0.00Open0.05Pre Close0 Volume123 Open Interest2.00Strike Price0.00Turnover368.81%IV155.61%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2025Delta0.4665Gamma16.04Leverage Ratio-0.0056Theta0.0000Rho3.25Eff Leverage0.0005Vega
Sangamo Therapeutics Stock Discussion
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Gene Editi
https://www.moomoo.com/t/news/post/43596799/BYnzVJBmba
Bought big Friday, looks like I made the right call. GLTA
No comment yet